Completed PHASE2 INTERVENTIONAL 1-arm NCT04188860

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial

Sponsor: Lei Li

Conditions Anti-PD-1 Antibody Chemotherapy Immunotherapy Persistent Advanced Cervical Carcinoma Recurrent Cervical Carcinoma

Interventions A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel

Updated 6 times since 2020 Last updated: Mar 12, 2022 Started: Dec 6, 2019 Primary completion: Jan 6, 2022 Completion: Mar 6, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04188860, this PHASE2 trial focuses on Anti-PD-1 Antibody and Chemotherapy and remains completed. Sponsored by Lei Li, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2022 — Apr 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China